SCHEMBL10183241

SCHEMBL10183241

Cc1cc(C(=O)Nc2cccc(-c3cncc(C(=O)N=[S@](=O)(CC(=O)N(C)CCO)c4ccccc4)c3)c2)n(C)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.36
HTT P42858 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KDR P35968 8/20 0.35
PDGFRB P09619 6/20 0.35
BRAF P15056 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
FGFR1 P11362 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
MEN1 O00255 1/20 0.33
AURKA O14965 1/20 0.33
KIT P10721 1/20 0.33
FLT1 P17948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835405 0.89 KDR (0.49) KDRPDGFRB
SCHEMBL848467 0.89 KDR (0.49) KDRPDGFRB
SCHEMBL10182239 0.88 KDR (0.36) MAPK1LMNASMN1; SMN2KMT2AGAA
SCHEMBL871802 0.87 KMT2A (0.42) MAPK1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL869137 0.87 BRAF (0.37) MAPK1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL869452 0.87 KDR (0.44) MAPK1LMNASMN1; SMN2KMT2AGAA
SCHEMBL869955 0.84 LMNA (0.38) MAPK1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL872089 0.84 KMT2A (0.36) MAPK1HTTLMNASMN1; SMN2KMT2A
SCHEMBL10183863 0.84 KDR (0.35) MAPK1LMNASMN1; SMN2KMT2AGAA
SCHEMBL10182242 0.84 KDR (0.38) MAPK1LMNASMN1; SMN2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383825-B2 Kinase inhibitors ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20120207810-A1 Kinase Inhibitors SPADA LON T (US) 2012-08-16 US disclosed
US-8143410-B2 Kinase inhibitors ALLERGAN, INC. (US) 2012-03-27 US disclosed
US-20110263611-A1 Kinase Inhibitors ALLERGAN, INC. 2011-10-27 US disclosed
US-20090196906-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263611-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 MAPK1 31/4885HTT 4564/4885ALDH1A1 2605/4885
US-20120207810-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 MAPK1 31/4885HTT 4564/4885ALDH1A1 2605/4885
US-20090196906-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 MAPK1 31/4885HTT 4564/4885ALDH1A1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.